Navigation Links
Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Date:8/19/2007

SAN DIEGO, Aug. 14 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today unaudited financial results for the second quarter and six months ended June 30, 2007. Cadence reported a net loss for the second quarter of 2007 of $14.9 million, or $0.52 per share, compared to a net loss of $6.2 million, or $4.92 per share, in the second quarter of 2006. For the six months ended June 30, 2007, the company reported a net loss of $24.5 million, or $0.86 per share, compared to a net loss of $35.4 million, or $28.50 per share for the six months ended June 30, 2006.

As of June 30, 2007, Cadence held cash and cash equivalents of $66.9 million.

"We remain keenly focused on executing the development programs for our two Phase III product candidates, intravenous acetaminophen and Omigard(TM)," said Ted Schroeder, Cadence's President and Chief Executive Officer. "As a result, we are on track to meet our clinical development and pre-commercialization manufacturing objectives for both product candidates. In particular, we are pleased with the recent execution of a development and supply agreement for IV acetaminophen with Baxter Healthcare, a leading global contract manufacturer, which we believe will position us to meet the anticipated demand for this important product candidate upon commercialization and for several years thereafter."

Financial Results

Total operating expenses for the second quarter of 2007 were $15.7 million, compared to $6.6 million for the second quarter of 2006. The increase in operating expenses was p
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... BOSTON and TEL AVIV, Israel ... ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in ... , the Company,s President and Chief Executive Officer, and ... will participate in the Benchmark Company, LLC One-on-One Investor Conference ... East Wisconsin Ave., Milwaukee, WI. ...
(Date:5/24/2013)... 24, 2013 Senomyx , Inc. (NASDAQ: ... science technologies to discover, develop, and commercialize novel flavor ... , Ph.D., the Company,s Vice President, Biology and ... & Corporate Communications, will present an overview of Senomyx,s ... a.m. Eastern Time (7:25 a.m. Pacific Time) during the ...
(Date:5/24/2013)... Texas (PRWEB) May 24, 2013 ... benchmarking survey on kinase profiling carried out in ... details of the breakdown of the responses for ... the future (2015). It also highlights some interesting ... survey groupings. Two bottom-up models were developed to ...
(Date:5/24/2013)... Toronto, Canada (PRWEB) May 24, 2013 ... selective barriers, and uptake or efflux transporters at the ... may be related to unbound fractions in the tissue ... understanding of these disposition challenges is required to guide ... and to identify any species-dependent variables that may impact ...
Breaking Biology Technology:InspireMD To Participate In Benchmark Investor Conference On May 30th 2InspireMD To Participate In Benchmark Investor Conference On May 30th 3InspireMD To Participate In Benchmark Investor Conference On May 30th 4SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE 2Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 2Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 3Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 4DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2
... Inc. (NYSE: AOB ), a leading manufacturer and ... that it plans to release third quarter 2007 financial ... The company will hold a conference call on ... fiscal third quarter results. Listeners may access the,call by ...
... Kosan Biosciences,Inc. (Nasdaq: KOSN ) today ... Day on Wednesday, October 31, 2007, beginning at ... In addition to,presentations by Kosan,s Executives, Robert G. ... and Pieter Timmermans, Ph.D., Senior,Vice President, Drug Discovery ...
... Oct. 24 Codexis, Inc., a private,biotechnology company ... the opening of Codexis Laboratories Singapore,Pte. Ltd. (CLS). ... Asia, and,is an expansion of the company,s research ... will support the company,s pharmaceuticals business in,both the ...
Cached Biology Technology:American Oriental Bioengineering Announces Reporting Date for Third Quarter 2007 Financial Results 2Kosan Biosciences to Host Research & Development Day on October 31, 2007 2Kosan Biosciences to Host Research & Development Day on October 31, 2007 3Codexis Opens Singapore Laboratory 2
(Date:5/23/2013)... HOUSTON (May 23, 2013) A new report ... responsible for helping pupils engage in at least 60 ... school day. , No more than half of American ... hour of vigorous or moderate intensity physical activity daily, ... , "Because children are in school for nearly half ...
(Date:5/23/2013)... team reveal the interplay of brain chemicals which help ... Trust and BBSRC. , By changing the way ... abilities. While these changes can affect the strength of ... of that response. , Lead author Alex ... with others, you can make yourself better heard by ...
(Date:5/22/2013)... in fuel cell powered buses, including a team ... electrode degradation processes and bus membrane durability. , ... degradation stressors in the operating cycle of the ... of the study, led by SFU graduate student ... study at Burnaby-based Ballard Power Systems and funded ...
Breaking Biology News(10 mins):Schools should provide students with daily physical activity, IOM recommends 2Tests lead to doubling of fuel cell life 2
... written by Rosa Binimelis, Walter Pengue and Iliana Monterroso, ... University of Barcelona, University of Buenos Aires and the ... The article describes the geographical advance of the invasion ... the invasion process to discuss the major drivers and ...
... Supply Chain Council (SCC) announced today it has joined ... offer a unique new program that will enhance the ... professionals.SCC is the world,s leading authority on supply chain ... while APICS is the leader in operations management and ...
... ALEXANDRIA, Va., May 7 Today, the White House ... funding for the Carl D. Perkins Career and Technical ... Act is the primary source of federal funding that ... careers. The Association for Career and Technical Education (ACTE) ...
Cached Biology News:Weed resistance to glyphosate in genetically modified soybean cultivation in Argentina 2Supply Chain Council Partners With APICS The Association for Operations Management 2Obama Budget Level Funds Career Technical Education 2Obama Budget Level Funds Career Technical Education 3
Anti-human C5a/C5a des-Arg (neo-epitode), Clone 2952, Monoclonal Antibody...
Reacts with the 80 kDa fragment of the M-chain of human merosin....
ICAD / DFF45 (NT) Affinity Purified Polyclonal Antibody...
... Rabbit polyclonal to ZFP91 ( ... Antigen: Synthetic ... 280 of human ZFP91. (Note: ... Entrez ...
Biology Products: